EffRx Pharmaceuticals is a lean & agile integrated market-oriented biopharma focused on niche therapeutics in Europe and in Switzerland. Our business strategy focuses on successfully shaping the late development and launch of therapeutics for patients suffering from niche and rare diseases.
We tailor the late clinical & regulatory development of niche and orphan medicines to build powerful, differentiated launch propositions, to ensure accelerated market entry and to maximize long term market opportunities.
Our business model centers around providing superior clinical and commercial value propositions for physicians, payers and patients.
Our vision is to be the preferred and dedicated partner in Europe and Switzerland for the late clinical development, approval and valorization of emerging biopharmaceuticals.
We have a very effective team with proven cross-functional competencies in Clinical Development, Medical Affairs, Regulatory Affairs, Market Access, Marketing, Brand & Launch Management, Business Development & Alliance Management, Quality Management, Operations & Supply Chain.
EffRx pro-actively seeks in-licensing opportunities for Europe in the therapeutic areas of its primary interest and for rare diseases, where EffRx has received an orphan drug designation (ODD) from FDA for EX404.